#biotech
biotech
223,418 views
350 Discussing
Hot
Latest
🚨 $XBI
USDT Perp is almost live on Binance Futures 🚨
Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥
Pair: XBIUSDT Perp
Underlying asset: SPDR S&P Biotech ETF (XBI)
Platform: Binance Futures
Status: Pre-launch / trading not open yet
Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot
Right now, price and market stats are still inactive:
Last Price: 0.00
Mark Price: 0.00
24h High / Low: 0.00 / 0.00
24h Volume: 0.00
That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format.
What to watch at open:
First few candles for volatility spike
Funding and liquidity behavior
Early long/short battle after listing goes live
Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡
#Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech
ParadigmRaises$1.2BThirdFundForAIAndRobotics
#FedMinutesShowSplitOnRateHikes
#SonyGetsOCCApprovalForStablecoinTrust
#KOSPIJumpsNearly4%To7539
#SKHynixUSListingOversubscribed7x
USDT Perp is almost live on Binance Futures 🚨
Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥
Pair: XBIUSDT Perp
Underlying asset: SPDR S&P Biotech ETF (XBI)
Platform: Binance Futures
Status: Pre-launch / trading not open yet
Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot
Right now, price and market stats are still inactive:
Last Price: 0.00
Mark Price: 0.00
24h High / Low: 0.00 / 0.00
24h Volume: 0.00
That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format.
What to watch at open:
First few candles for volatility spike
Funding and liquidity behavior
Early long/short battle after listing goes live
Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡
#Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech
ParadigmRaises$1.2BThirdFundForAIAndRobotics
#FedMinutesShowSplitOnRateHikes
#SonyGetsOCCApprovalForStablecoinTrust
#KOSPIJumpsNearly4%To7539
#SKHynixUSListingOversubscribed7x
$BIO
Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly.
#BIO #BİO #Biotech
Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly.
#BIO #BİO #Biotech
$BIO
BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.
A break could open the way for an upside move, and the risk-reward ratio is clean from here.
Do you support the bid or wait for a breakout?
#BIO #BİO #Biotech
BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.
A break could open the way for an upside move, and the risk-reward ratio is clean from here.
Do you support the bid or wait for a breakout?
#BIO #BİO #Biotech
📈 #ModernaRisesOver12% — Biotech Giant Surges on New Pipeline Data
Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines.
#ModernaRisesOver12% #Biotech #MRNA
Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines.
#ModernaRisesOver12% #Biotech #MRNA
MRNAonAlpha
MRNAUS-0.03%
$BIO
The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.
#BİO #Biotech #TradingTales
The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.
#BİO #Biotech #TradingTales
🚨🦟 $GOOGL -BACKED MOSQUITO RELEASE? THE INTERNET IS PANICKING... BUT HERE'S WHAT THEY'RE NOT TELLING YOU 👀👇
32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸
Sounds terrifying, right? 😳
But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇
🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.
The mission? 🎯
✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides
Here's where things get interesting... 👀
❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.
And male mosquitoes don't bite humans. 🦟🚫
Instead, they carry a naturally occurring bacterium called Wolbachia.
When they mate with wild female mosquitoes:
📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time
💡 Why are scientists exploring this?
Because some mosquito species are becoming increasingly resistant to traditional pesticides.
Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎
🤔 The bigger question:
If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...
Would YOU support releasing millions of non-biting mosquitoes? 👇
🔥 YES — if it saves lives 😬 NO — too many unknown risks
Drop your answer below and let's discuss! 💬
$STRAX
#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder
📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸
Sounds terrifying, right? 😳
But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇
🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.
The mission? 🎯
✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides
Here's where things get interesting... 👀
❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.
And male mosquitoes don't bite humans. 🦟🚫
Instead, they carry a naturally occurring bacterium called Wolbachia.
When they mate with wild female mosquitoes:
📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time
💡 Why are scientists exploring this?
Because some mosquito species are becoming increasingly resistant to traditional pesticides.
Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎
🤔 The bigger question:
If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...
Would YOU support releasing millions of non-biting mosquitoes? 👇
🔥 YES — if it saves lives 😬 NO — too many unknown risks
Drop your answer below and let's discuss! 💬
$STRAX
#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder
📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)
The biggest wealth transfer in crypto won't come from finance. It will come from biology.
Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.
The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.
Blockchain infrastructure is completely restructuring this system.
Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.
If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.
The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.
$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.
The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.
Blockchain infrastructure is completely restructuring this system.
Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.
If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.
The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.
$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends
Parabilis raises 670M in record biotech IPO, signaling renewed risk appetite in healthcare innovation
🧬 Parabilis Medicines began trading on Nasdaq under the ticker PBLS after selling 33.5 million shares at 20 USD per share, raising around 670 million USD through its IPO. The size of the deal makes it one of the most notable biotech listings of 2026.
🏛️ The key point is not only the capital raised, but also the fact that the offering was upsized while the biotech IPO market remains selective. This suggests investors are still willing to back companies with differentiated technology, clear clinical programs and strong long-term potential.
🤝 Regeneron also joined a concurrent private placement of around 75 million USD and had already entered a strategic collaboration with Parabilis in May. The involvement of a major pharmaceutical name adds more attention to Helicon, Parabilis’ peptide platform designed to reach intracellular targets that traditional drugs often struggle to address.
🔬 The new funding will support the development of zolucatetide, the company’s lead program targeting desmoid tumors and other cancers linked to the Wnt/β-catenin pathway. Parabilis aims to move this program closer to Phase 3 development in 2027.
⚖️ Despite the positive IPO narrative, Parabilis remains a clinical-stage biotech company with meaningful trial risk. After the initial listing phase, clinical data, pipeline execution and institutional demand will matter more than the headline IPO size.
#Biotech $BTC $BNB $HNT
🧬 Parabilis Medicines began trading on Nasdaq under the ticker PBLS after selling 33.5 million shares at 20 USD per share, raising around 670 million USD through its IPO. The size of the deal makes it one of the most notable biotech listings of 2026.
🏛️ The key point is not only the capital raised, but also the fact that the offering was upsized while the biotech IPO market remains selective. This suggests investors are still willing to back companies with differentiated technology, clear clinical programs and strong long-term potential.
🤝 Regeneron also joined a concurrent private placement of around 75 million USD and had already entered a strategic collaboration with Parabilis in May. The involvement of a major pharmaceutical name adds more attention to Helicon, Parabilis’ peptide platform designed to reach intracellular targets that traditional drugs often struggle to address.
🔬 The new funding will support the development of zolucatetide, the company’s lead program targeting desmoid tumors and other cancers linked to the Wnt/β-catenin pathway. Parabilis aims to move this program closer to Phase 3 development in 2027.
⚖️ Despite the positive IPO narrative, Parabilis remains a clinical-stage biotech company with meaningful trial risk. After the initial listing phase, clinical data, pipeline execution and institutional demand will matter more than the headline IPO size.
#Biotech $BTC $BNB $HNT
$BIO is gaining some solid attention today.The token has been showing decent volume and steady buying interest. With its focus on decentralized biotechnology, longevity, and health data, $BIO is becoming one of the more unique and promising projects in the BioTech x Crypto space.Many traders are now watching if it can break its recent resistance and move higher.Are you holding $BIO or planning to enter on this move?
Drop your thoughts #BIO #BioTech
Drop your thoughts #BIO #BioTech
Metis’ recent trend is a bit interesting—double-line resonance is worth watching.
Technical analysis: The AI Agent has completed an upgrade, and on-chain narratives and overall appeal have improved noticeably, with ecosystem activity rebounding.
Fundamentals: Metis’ subsidiary, Metis TechBio, secured a $1.6 billion drug licensing agreement. This biotech “side business” directly adds another layer of leverage to market confidence.
Current data:
· Price $2.73
· 24h trading volume $2.15 million
· Market cap $20.61 million
The market-cap scale is still quite small, and with the dual catalysts of AI + BioTech, the upside room isn’t low. However, trading volume is relatively thin compared to market cap, so volatility may be amplified. If chasing, keep position size under control; confirmation on a pullback is more reliable.
The key focus is whether the upgraded on-chain data can continue to deliver, and how the subsequent implementation timeline of the licensing agreement unfolds. No matter how good the story is, you still need to see whether the on-chain activity and financial reports can back it up.
$METIS #Metis #AI #BioTech
Technical analysis: The AI Agent has completed an upgrade, and on-chain narratives and overall appeal have improved noticeably, with ecosystem activity rebounding.
Fundamentals: Metis’ subsidiary, Metis TechBio, secured a $1.6 billion drug licensing agreement. This biotech “side business” directly adds another layer of leverage to market confidence.
Current data:
· Price $2.73
· 24h trading volume $2.15 million
· Market cap $20.61 million
The market-cap scale is still quite small, and with the dual catalysts of AI + BioTech, the upside room isn’t low. However, trading volume is relatively thin compared to market cap, so volatility may be amplified. If chasing, keep position size under control; confirmation on a pullback is more reliable.
The key focus is whether the upgraded on-chain data can continue to deliver, and how the subsequent implementation timeline of the licensing agreement unfolds. No matter how good the story is, you still need to see whether the on-chain activity and financial reports can back it up.
$METIS #Metis #AI #BioTech
Verified
$METIS Recent performance has clearly rebounded, and the dual-engine drive is worth watching:
First, at the ecosystem level, the AI Agent upgrade has been implemented, and on-chain application scenarios and their attractiveness are rising in tandem, providing a foundation for long-term valuation. Second, at the business level, Metis TechBio under the company has reached a $1.6 billion drug licensing agreement, directly connecting the cash-flow expectations of traditional biotech to the token narrative and reigniting market confidence.
At the current price of $2.73, the market cap is only about $20.61 million, with $2.15 million in 24-hour trading volume. Given the scale of business progress, valuation upside potential is not small; however, a small market cap also means volatility will be amplified. It’s advisable to watch whether volume continues to expand, and then decide whether this is the start of a trend or merely a sentiment-driven pulse.
The combination of technical upgrades plus real-world business execution is the core logic behind this rebound. Going forward, it will be more important to track AI Agent usage data and the milestone cadence in TechBio.
#Metis #AI #BioTech
First, at the ecosystem level, the AI Agent upgrade has been implemented, and on-chain application scenarios and their attractiveness are rising in tandem, providing a foundation for long-term valuation. Second, at the business level, Metis TechBio under the company has reached a $1.6 billion drug licensing agreement, directly connecting the cash-flow expectations of traditional biotech to the token narrative and reigniting market confidence.
At the current price of $2.73, the market cap is only about $20.61 million, with $2.15 million in 24-hour trading volume. Given the scale of business progress, valuation upside potential is not small; however, a small market cap also means volatility will be amplified. It’s advisable to watch whether volume continues to expand, and then decide whether this is the start of a trend or merely a sentiment-driven pulse.
The combination of technical upgrades plus real-world business execution is the core logic behind this rebound. Going forward, it will be more important to track AI Agent usage data and the milestone cadence in TechBio.
#Metis #AI #BioTech
$METIS In recent times, the fundamentals have shown clear changes: on the ecosystem side, the AI Agent upgrade has been completed, and the on-chain narrative has been reactivated; on the business side, the subsidiary Metis TechBio has finalized a $1.6 billion drug licensing agreement, bringing the project and real cash flows onto the same table.
The current price is about $2.73, with $2.15 million in trading volume over the past 24 hours. The market cap is only $20.61 million, which is a typical small-cap, high-volatility range. The technical upgrade brings more use cases, and biotech collaborations provide confidence as endorsements. The fact that both lines resonate at the same time point is the core logic behind this round of strength.
That said, it’s worth noting that relatively thin liquidity means both upside and downside moves can be amplified. Before chasing the price, it’s recommended to first check order-book depth, and to define your position size and stop-loss before entering—rather than after the trend deteriorates.
#Metis #AIAgent #BioTech
The current price is about $2.73, with $2.15 million in trading volume over the past 24 hours. The market cap is only $20.61 million, which is a typical small-cap, high-volatility range. The technical upgrade brings more use cases, and biotech collaborations provide confidence as endorsements. The fact that both lines resonate at the same time point is the core logic behind this round of strength.
That said, it’s worth noting that relatively thin liquidity means both upside and downside moves can be amplified. Before chasing the price, it’s recommended to first check order-book depth, and to define your position size and stop-loss before entering—rather than after the trend deteriorates.
#Metis #AIAgent #BioTech
Metis Recent market moves are not happening out of nowhere. On one side, on-chain AI Agent upgrades have pulled the ecosystem’s technical narrative back into focus; on the other, its subsidiary, Metis TechBio, has landed a $1.6 billion pharmaceutical licensing deal. This kind of “crypto + biotech” combination is not common.
At the current quote of $METIS , price is $2.73, with 2.15 million traded in 24h, and a market cap of $20.61 million. Because the float is relatively small, fundamental changes can be amplified quickly. In the short term, the AI upgrade brings marginal improvements to on-chain activity, while TechBio’s commercialization rollout provides a new valuation anchor for the medium to long term.
That said, both market cap and trading volume are not particularly thick, so sentiment shifts can happen fast. If you want to participate, it’s more suitable to buy in batches and validate with on-chain data, rather than chasing the emotional high point.
#Metis #AIAgent #Biotech
At the current quote of $METIS , price is $2.73, with 2.15 million traded in 24h, and a market cap of $20.61 million. Because the float is relatively small, fundamental changes can be amplified quickly. In the short term, the AI upgrade brings marginal improvements to on-chain activity, while TechBio’s commercialization rollout provides a new valuation anchor for the medium to long term.
That said, both market cap and trading volume are not particularly thick, so sentiment shifts can happen fast. If you want to participate, it’s more suitable to buy in batches and validate with on-chain data, rather than chasing the emotional high point.
#Metis #AIAgent #Biotech
ALERT 🚨 Bullish momentum builds for $SCRT (SECRET) as order blocks surface above the 200 day volume 📈. $NVDAB (NVIDIA) pushes innovation in AI, boosting liquidity and investor sentiment 💡. $BIO (BIO) rides biotech ecosystem growth, tightening trading activity 🧪. Strong buy across the trio. #SecretNetwork #NVIDIA #Biotech
#modernarisesover12% 🚀 $MRNAon
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
$LLY NEXT WEIGHT-LOSS BLOCKBUSTER – RETATRUTIDE FUELS A BULLISH PARADIGM SHIFT 🟢💊
📌 While traders chase crypto pumps, smart money is quietly accumulating $LLY ahead of a potential $3.8B revenue stream from Retatrutide—a triple-hormone GLP-1/GIP/glucagon therapy that crushed phase 3 trials with 22.6% weight loss in obese heart patients. 📊 The 2% price reaction is just the surface; underneath, 20 out of 22 analysts rate it a Buy with a $1,294 average target, implying 17% upside from current levels.
💡 This is the kind of asymmetric risk-reward that institutional portfolios are built around. The delayed FDA filing (Q1 2027) only creates a deeper discount for patient capital. 💬 Do you have $LLY on your radar, or are you waiting for the clinical data to fully hit the mainstream? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #Biotech #WeightLossDrug #Pharma #Bullish
💎 🚀
📌 While traders chase crypto pumps, smart money is quietly accumulating $LLY ahead of a potential $3.8B revenue stream from Retatrutide—a triple-hormone GLP-1/GIP/glucagon therapy that crushed phase 3 trials with 22.6% weight loss in obese heart patients. 📊 The 2% price reaction is just the surface; underneath, 20 out of 22 analysts rate it a Buy with a $1,294 average target, implying 17% upside from current levels.
💡 This is the kind of asymmetric risk-reward that institutional portfolios are built around. The delayed FDA filing (Q1 2027) only creates a deeper discount for patient capital. 💬 Do you have $LLY on your radar, or are you waiting for the clinical data to fully hit the mainstream? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #Biotech #WeightLossDrug #Pharma #Bullish
💎 🚀
🚨 $LLY INSTITUTIONAL POSITIONING FOR THE NEXT WEIGHT LOSS BLOCKBUSTER 🚀💊
📊 Eli Lilly just confirmed plans to file for Retatrutide approval by Q1 2027 — a timeline shift that still sparked a 2% rally. 🦈 Smart money interprets this as a deliberate pace to perfect manufacturing quality before flooding the market.
💡 Phase 3 data is exceptional: 20.8% weight loss in obese diabetics and 22.6% in those with cardiovascular conditions — all via a triple-hormone mechanism (GLP-1 + GIP + glucagon). That’s a structural leap beyond current GLP-1 treatments. 📌 With 20/22 analysts rating it a Buy and a median price target of $1,294, the risk-reward remains institutionally rotated.
💬 Will Retatrutide help $LLY maintain its edge over Novo Nordisk in the global GLP-1 race, or is competition heating up more than expected? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #WeightLoss #Pharma #Biotech #GrowthStock
🚀 💎
📊 Eli Lilly just confirmed plans to file for Retatrutide approval by Q1 2027 — a timeline shift that still sparked a 2% rally. 🦈 Smart money interprets this as a deliberate pace to perfect manufacturing quality before flooding the market.
💡 Phase 3 data is exceptional: 20.8% weight loss in obese diabetics and 22.6% in those with cardiovascular conditions — all via a triple-hormone mechanism (GLP-1 + GIP + glucagon). That’s a structural leap beyond current GLP-1 treatments. 📌 With 20/22 analysts rating it a Buy and a median price target of $1,294, the risk-reward remains institutionally rotated.
💬 Will Retatrutide help $LLY maintain its edge over Novo Nordisk in the global GLP-1 race, or is competition heating up more than expected? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #WeightLoss #Pharma #Biotech #GrowthStock
🚀 💎
🔥🔥🔥$XRP ¡Mauricio joins the decentralized genetic identity revolution! 🇲🇺🧬
The global expansion of @DNAProtocol officially reaches Mauritius, marking a milestone in digital health infrastructure and #Web3 technology in Africa.
By integrating certified labs and clinics, the protocol will begin anchoring genomic identity data directly on the XRP Ledger (#XRPL). This advancement combines advanced cryptography and blockchain immutability to ensure:
🔒 Biological Sovereignty: Users maintain absolute and private control over their medical information.
🔐 Absolute Privacy: Integration of Zero-Knowledge Proofs (ZKP) to verify data without revealing sensitive information.
🛡️ Post-Quantum Security: Implementation of the NIST ML-DSA standard to protect records against future technological threats.
This deployment adds to previous successes in Morocco and Uganda, further consolidating the XRPL ecosystem as a fundamental pillar for decentralized and institutional identity management worldwide.
#blockchain #DigitalIdentity #Healthtech #XRPledger #Biotech
$BNB
$BTC
The global expansion of @DNAProtocol officially reaches Mauritius, marking a milestone in digital health infrastructure and #Web3 technology in Africa.
By integrating certified labs and clinics, the protocol will begin anchoring genomic identity data directly on the XRP Ledger (#XRPL). This advancement combines advanced cryptography and blockchain immutability to ensure:
🔒 Biological Sovereignty: Users maintain absolute and private control over their medical information.
🔐 Absolute Privacy: Integration of Zero-Knowledge Proofs (ZKP) to verify data without revealing sensitive information.
🛡️ Post-Quantum Security: Implementation of the NIST ML-DSA standard to protect records against future technological threats.
This deployment adds to previous successes in Morocco and Uganda, further consolidating the XRPL ecosystem as a fundamental pillar for decentralized and institutional identity management worldwide.
#blockchain #DigitalIdentity #Healthtech #XRPledger #Biotech
$BNB
$BTC
$MRNA PRICE TARGET RAISED TO $60 BY JPMORGAN 🔥
JPMorgan just lifted Moderna’s price target from $53 to $60 — a clear vote of confidence from one of the biggest banks on the Street. That’s a 13% upside from the old target, and this kind of institutional upgrade tends to attract follow-through buying in the days ahead.
The question is whether this is the start of a stronger trend or just a one-off analyst bump. Are you adding to your position or waiting for price action to confirm?
Not financial advice. Always manage your risk.
#MRNA #PriceTarget #Bullish #Upgrade #Biotech
🔥
JPMorgan just lifted Moderna’s price target from $53 to $60 — a clear vote of confidence from one of the biggest banks on the Street. That’s a 13% upside from the old target, and this kind of institutional upgrade tends to attract follow-through buying in the days ahead.
The question is whether this is the start of a stronger trend or just a one-off analyst bump. Are you adding to your position or waiting for price action to confirm?
Not financial advice. Always manage your risk.
#MRNA #PriceTarget #Bullish #Upgrade #Biotech
🔥
Log in to explore more content